COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Siva Dasa

Siva Dasa, PhDSiva Dasa, PhD
Scientist II, Pharmacology & Toxicology

Dr. Dasa joined Nanotechnology Characterization Laboratory (NCL) in May 2019 as a liposome formulation scientist with expertise extending into other lipid based nanoformulations. He has worked with liposomal formulations for many years, and has experience with both active and passive methods of encapsulating drugs for treatment of cancer and cardio-metabolic disorders. Other areas of expertise include identifying target-specific ligands using M13 phage display library screening for active delivery of nanoparticles, lipid and lipid-PEG modifications, and studying nanoparticle interaction with proteins.

Prior to joining NCL, Dr. Dasa served as an instructor at the University of Virginia (UVA) for 2 years and before that as a postdoctoral research fellow. While at UVA, he worked on projects in collaboration with AstraZeneca (Sweden) developing liposomal formulations for treating cardiovascular and metabolic disorders. During his time at UVA, he received a postdoctoral fellowship from the American Heart Association (AHA), and a R01 application funded by the NHLBI.

Dr. Dasa received a BSc Hons Biosciences (2002) and MSc Biotechnology (2004) from India, and a . MS Biology (2006) and PhD Biology (2011) from Illinois Institute of Technology, Chicago, with research conducted at Argonne National Laboratory. During his PhD, he worked on various projects including characterization of CA 125 using fluorescence correlation spectroscopy, development of fluorescent dye-micelles for CA 125 detection, T7 phage-based PET imaging probes for cancer, single cell multiplex RT PCR, and studying the nature of floating cells in human embryonic stem cell culture.